The labeling for Thrombin-JMI (topical bovine thrombin, from King Pharmaceuticals) has been updated to recognize the enhanced purification process that reduces bovine Factor V light chain content to undetectable levels. The presence of bovine Factor V in thrombin may elicit antibody formation that cross-reacts with human Factor V causing clinically significant coagulopathies.
Thrombin-JMI is indicated as an aid to hemostasis for oozing blood and minor bleeding from accessible capillaries and small veins, and as an adjunct for surgical hemostasis with an absorbable gelatin sponge. The high-purity formulation is expected to be available in March 2008.
For more information call (800) 776-3637 or visit www.kingpharm.com.